Our AIC™ Platform is prominently positioned in the field of immunocytokine development from multiple aspects, including cytokine selection and optimization, antibody selection and engineering, structural design and engineering and production through customized cell line. It is a comprehensive research engine that includes not only a pool of intact IgG antibodies and cytokines, but also functional antibody fragments and other types of immune system modulators. It is able to generate products ranging from immunocytokines to bifunctional fusion proteins. The products designed from the AIC™ Platform may not only include immunostimulants that directly activate both innate and adaptive immunity, but also immunosuppressors that reduce an overactive immune system. Therefore, AIC™ Platform enables us to enrich our pipeline with candidates for treatment of cancer and viral infection, and also candidates for the treatment of autoimmune diseases and emergency care against cytokine storm.
SunHo Armed ImmunoCytokine Platform AIC™
Our clinical stage drug candidates IAP0971, IAE0972 and IBB0979, and preclinical stage drug candidates ISH0988 and ISH0613 were developed based on the AIC™Platform.